Navigation Links
Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
Date:11/26/2008

VEDBAEK, Denmark, November 26 /PRNewswire-FirstCall/ -- Exiqon A/S, traded at the NASDAQ OMX Copenhagen ("EXQ"), reports continued strong growth in research product sales during the third quarter of 2008. Revenues were positively affected by the execution of a license agreement with Roche Diagnostics for use of Exiqon's LNA(TM) technology. Initial fourth quarter sales were negatively affected by supply of arrays that failed Exiqon's internal quality tests causing a slow down in executed sales orders. Although the supply problems have now been addressed, Exiqon revises its 2008 total year guidance of revenue of DKK 140-150 million to now DKK 120-130 million. As a result, a net loss of DKK 115-125 is now anticipated compared to previous expectations of a net loss of DKK 100-115 million.

    - Revenue in the third quarter of 2008 increased five fold on the
      year-earlier period to DKK 51.3 million, totaling DKK 95.8 million in
      the first nine months of 2008.

    - Compared third quarter last year product sales increased by 329% to DKK
      28 million totaling DKK 68,5 million in the first nine months of 2008.
      Research product sales grew organically by 141%.

    - Net loss for the third quarter of 2008 was DKK 10.1 million totaling
      DKK 73.6 million in the first nine months of 2008. EPS amounted to DKK
      -0.35 in the third quarter of 2008 and DKK -2.55 in the first nine
      months of 2008.

    - License granted to Roche Diagnostics for use of Exiqon's proprietary
      LNA(TM) detection technology in a new product line for RealTime ready
      qPCR assays demonstrates the value of LNA(TM) as a detection
      technology.

    - The integration of former Oncotech Inc - now Exiqon Diagnostics Inc -
      remains on track for the first miRNA diagnostic product launch to be
      announced in December 2008.

Lars Kongsbak, President and CEO says: "Product demand remains stron
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
2. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
3. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
4. Misonix Announces Interim Distribution Agreement for Italy
5. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
6. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
7. Arpida Reports Interim Results for Six Months to 30 June 2008
8. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
9. LPBP Inc. - Re-filing certification of interim filings
10. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... Total Site Solutions,(TSS), a Fortress International Group Company ... the planning, design and development of,mission-critical facilities today ... industry has awarded them the construction,management phase of ... performed technology consulting services to analyze,short term and ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
... leader in,the rapidly evolving field of cancer molecular diagnostics, ... Lindenbergh as Chairman of its,Supervisory Board. Hessel Lindenbergh ... ING,Group N.V.. Currently, Mr. Lindenbergh is chairman of the ... the Royal Numico, Petroplus,International and Gamma Holding. Mr. Lindenbergh ...
Cached Biology Technology:Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 3Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board 2
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... a study has compared water quality trends in forested streams ... or land cover changes. The study, which draws on ... states and Puerto Rico, underscores the value of long-term data ... in streams and rivers. It is published in the current ...
... sick with colon cancer, received a blood transfusion. Then, unexpectedly, ... on her case, the French medical journal Revue D,Hmatologie identified ... it turns out, Mrs. Vel had developed a potent antibody ... of most people in the worldbut not found on her ...
... Philanthropist, businessman and community leader John Moores has given ... fund the development of a new field test for ... tens of millions of people in Africa, Latin America ... John,s generosity and foresight," said Michael A. Marletta, president ...
Cached Biology News:Study explores long-term water quality trends in near-pristine streams 2Baffling blood problem explained 2Baffling blood problem explained 3John Moores gives $2 million to Scripps Research to develop river blindness field test 2